Mario Pirisi
A5072500126- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Systemic Lupus Erythematosus Research
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Liver Diseases and Immunity
- Vitamin D Research Studies
- COVID-19 and healthcare impacts
- Liver physiology and pathology
- Phagocytosis and Immune Regulation
- Systemic Sclerosis and Related Diseases
- Cancer, Lipids, and Metabolism
- SARS-CoV-2 and COVID-19 Research
- Pancreatitis Pathology and Treatment
- Renal Diseases and Glomerulopathies
- Diabetes and associated disorders
- Organ Transplantation Techniques and Outcomes
- Colorectal Cancer Treatments and Studies
- Pulmonary Hypertension Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Iron Metabolism and Disorders
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2016-2025
Azienda Ospedaliero Universitaria Maggiore della Carita
2016-2025
Scuola Superiore Sant'Anna
2025
Fondazione Toscana Gabriele Monasterio
2025
Ospedale Maggiore
2021-2023
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2021-2023
Azienda Ospedaliera Universitaria Senese
2023
Policlinico S.Orsola-Malpighi
2023
Ospedale San Paolo
2023
IRCCS Ospedale San Raffaele
2023
<h3>Importance</h3> Although plenty of data exist regarding clinical manifestations, course, case fatality rate, and risk factors associated with mortality in severe coronavirus disease 2019 (COVID-19), long-term respiratory functional sequelae survivors COVID-19 are unknown. <h3>Objective</h3> To evaluate the prevalence lung function anomalies, exercise impairment, psychological among patients hospitalized for COVID-19, 4 months after discharge. <h3>Design, Setting, Participants</h3> This...
Abstract The SARS-CoV-2 pandemic significantly affected oncology practice across the globe. There is uncertainty as to contribution of patients' demographics and oncologic features severity mortality from COVID-19 little guidance role anticancer anti–COVID-19 therapy in this population. In a multicenter study 890 patients with cancer confirmed COVID-19, we demonstrated worsening gradient breast hematologic malignancies showed that male gender, older age, number comorbidities identify subset...
Abstract Many coronavirus disease 2019 (Covid-19) survivors show symptoms months after acute illness. The aim of this work is to describe the clinical evolution Covid-19, one year discharge. We performed a prospective cohort study on 238 patients previously hospitalized for Covid-19 pneumonia in 2020 who already underwent follow-up 4 post-Covid-19. 200 consented participate 12-months assessment, including: pulmonary function tests with diffusing lung capacity carbon monoxide (DLCO);...
Abstract The course of hepatitis C virus (HCV) infection carriers with normal/near-normal aminotransferases (NALT) is usually mild; however, in a few, fibrosis progression occurs. We aimed to verify whether monitoring by liver biopsy might be replaced noninvasive methods and identify factors associated patients persistently normal alanine aminotransferases. studied 40 untreated HCV-RNA–positive subjects (22 male; median age, 44 years), who underwent two biopsies, interval 78.5 months, during...
Diabetes is characterized by the existence of a thrombosis-prone condition, possibly related to hyperglycemia. However, mechanism linking hyperglycemia activation coagulation cascade still unclear. It has been recently suggested that diabetes accompanied increased oxidative stress. In this work, possibility stress may be involved in hyperglycemia-induced evaluated. Prothrombin fragment 1 + 2 (F1+2), which represents reliable marker amount thrombin released circulation, chosen for studying...
The staging of liver fibrosis is pivotal for defining the prognosis and indications therapy in hepatitis C. Although biopsy remains gold standard, several noninvasive methods are under evaluation clinical use. aim this study was to validate recently described sequential algorithm (SAFE) biopsy, which detects significant (> or =F2 by METAVIR) cirrhosis (F4) combining AST-to-platelet ratio index Fibrotest-Fibrosure, thereby limiting cases not adequately classifiable markers. Hepatitis C virus...
The widely accepted interleukin-28B (IL-28B) rs12979860 C/T polymorphism and the more recently proposed vitamin D serum concentration are two novel predictors of response to antiviral treatment in chronic hepatitis C virus (HCV) infection. This study aimed verify whether IL-28B pretreatment levels have independent or complementary roles predicting rates sustained viral (SVR). present included 211 consecutive, treatment-naïve HCV patients who had their 25-OH level genotype determined....
Thrombocytopenia may be associated with increased bleeding risk impacting timing and outcome of invasive procedures in patients chronic liver disease (CLD). Lusutrombopag, a small‐molecule, thrombopoietin (TPO) receptor agonist, was evaluated as treatment to raise platelet counts (PCs) thrombocytopenia CLD undergoing procedures. L‐PLUS 2 global, phase 3, randomized, double‐blind, placebo‐controlled study. Adults baseline PCs < 50 × 10 9 /L were randomized receive once‐daily lusutrombopag...
Abstract Clinical features and natural history of coronavirus disease 2019 (COVID-19) differ widely among different countries during phases the pandemia. Here, we aimed to evaluate case fatality rate (CFR) identify predictors mortality in a cohort COVID-19 patients admitted three hospitals Northern Italy between March 1 April 28, 2020. All these had confirmed diagnosis SARS-CoV-2 infection by molecular methods. During study period 504/1697 died; thus, overall CFR was 29.7%. We looked for...
Aliment Pharmacol Ther 2011; 34: 1202–1216 Summary Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology chronic liver disease (CLD) and the stages hepatic fibrosis, but large-scale studies are pending. Aim To investigate effect aetiogy on performance biomarkers. Methods A total 2411 patients with compensated CLD (HCV = 75.1%, HBV 10.5%, NASH 7.9%, HIV/HCV 6.5%) were consecutively enrolled in 9 centres. APRI, Forns'index, Lok index, AST-to-ALT ratio,...
Abstract Background and aim: The PNPLA3 rs738409 C>G polymorphism has been found to be strongly associated with non‐alcoholic fatty liver disease alcoholic disease. Whether the could a risk factor for development of hepatocellular carcinoma (HCC) in cirrhosis patients is unknown. Methods: This study included 483 (344 males) consecutive Italian Caucasian ethnicity affected by cirrhosis, whom 279 had undergone transplantation end‐stage while 204 referred our transplant unit diagnosis...
The heterogeneity of intermediate-stage hepatocellular carcinoma (HCC) and the widespread use transarterial chemoembolization (TACE) outside recommended guidelines have encouraged development scoring systems that predict patient survival. aim this study was to build validate statistical models offer individualized survival prediction using response TACE as a variable.Clinically relevant baseline parameters were collected for 4,621 patients with HCC treated at 19 centers in 11 countries. In...
BACKGROUND: COVID-19 has been mainly investigated concerning the acute and subacute phase implications management. Meanwhile, few studies focused on midterm sequelae, which still remain largely unknown.AIM: To assess physical performance of survivors at 3 to 6 months from Hospital discharge.DESIGN: A cross-sectional study mid-term functional outcomes evaluation in survivors.SETTING: Outpatients who had previously hospitalized due March May 2020 University Novara, Italy.POPULATION: We...
Non-alcoholic fatty liver disease (NAFLD) is a challenging caused by multiple factors, which may partly explain why it still remains an orphan of adequate therapies. This review highlights the interaction between oxidative stress (OS) and disturbed lipid metabolism. Several reactive oxygen species generators, including those produced in gastrointestinal tract, contribute to lipotoxic hepatic (and extrahepatic) damage acids great variety their biologically active metabolites “multiple...
Whether patients with Child-Pugh class B (CP-B) cancer unresectable hepatocellular carcinoma (uHCC) benefit from active anticancer treatment vs best supportive care (BSC) is debated.
Background and Aims: Unlike other malignancies, hepatic functional reserve competes with tumor progression in determining the risk of mortality from hepatocellular carcinoma (HCC). However, relative contribution decompensation over influencing overall survival (OS) has not been assessed combination immunotherapy recipients. Approach Results: From AB-real observational study (n = 898), we accrued 571 patients advanced/unresectable carcinoma, Child-Pugh A class treated frontline atezolizumab +...